ClinicalTrials.gg
RecruitingNCT07210606CSA-HFUpdated Oct 13, 2026

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

A Phase 4 interventional study of Trazodone + positive airway pressure (PAP) therapy and Oxygen + positive airway pressure (PAP) therapy in Sleep Disordered Breathing and Able Bodied, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionSleep Apnea, CentralRegistry: Sleep Apnea SyndromesReclassifiedWhy we changed it
Registry
Sleep Apnea Syndromes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Apnea, Central
Why
  1. The study's title name Sleep Apnea, Central, a narrower term within Sleep Apnea Syndromes.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Sleep Apnea, Central with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Sleep Apnea, Central · United States.

Planned enrollment
3rd of 29
200 · median 44
Started
2026
with 1 other
Phase 4
4 of 36
2 open now
Registered
35th of 36
by date
Lead sponsor
5 of 36
VA Office of Research and Development

Among the 36 studies in Sleep Apnea, Central with a site in United States, this one is the 3rd largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 4, and was the 35th registered.

Sleep Apnea, Central

96 studies on the registry are indexed under Sleep Apnea, Central; 18 are open to participants now.

Browse Sleep Apnea, Central studies →

Open to participants now

4 of the 36 studies in Sleep Apnea, Central with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Sleep Apnea, Central studies recruiting now, 8 (62%) set no upper age limit and 3 (23%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Sleep Apnea, Central with a site in United States, or all of them as a file.
02

Study summary

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

Read the detailed description

The objective in this project is to test mechanistic pathways to inform future clinical studies investigating the potential treatment of central sleep apnea (CSA) in Veterans with heart failure and reduced ejection fraction (HF). The long-term goal is to transform the care of Veterans living with these two conditions. The investigators will test two key determinants of recurrent CSA in Veterans with HF: augmented peripheral chemoreceptor activity and respiratory arousals. Specifically, the project will utilize a novel PAP plus approach, combining PAP therapy to alleviate upper airway obstruction with a specific intervention to target the mechanistic underpinnings of CSA. The experiments will capitalize on the plasticity of the carbon dioxide (CO2) reserve as the gateway to the resolution of CSA. The investigators will suppress arousals or dampen augmented PCR activity while maintaining upper airway patency with PAP. The long-term goal is to inform future multi-modality intervention studies. To this end, the following Specific Aims will be addressed in Veterans with HF and CSA. Specific Aim (1): To determine the effect of decreasing respiratory arousals on the propensity to CSA. The investigators hypothesize that combined PAP and trazodone therapy will be superior to PAP alone in elevating the arousal threshold, widening the CO2 reserve (primary outcome), and decreasing CSA indices. Specific Aim (2): To determine the effect of decreased peripheral chemoreceptor sensitivity on the propensity to CSA. The investigators hypothesize that combined PAP and supplemental O2 (targeting peripheral chemoreceptor sensitivity) will be superior to PAP alone in widening the CO2 reserve (primary outcome), reducing controller gain, and decreasing CSA indices. The proposed studies are innovative, testing mechanistic "PAP Plus" approach targeting underlying causes of CSA and alleviating upper airway obstruction with PAP. These studies will inform future clinical trials to transform central apnea care in patients with heart failure.

03

Conditions studied

  • Sleep Disordered Breathing
  • Able Bodied

Keywords

  • Central Sleep Apnea
  • Polysomnography (PSG)
  • Respiratory Arousal Threshold
  • Apnea Hypopnea Index
  • Central Apnea Hypopnea Index
  • Breathing Instability
  • Apneic Threshold (AT)
  • Peripheral Chemoreflex Sensitivity
  • CO2 reserve
  • Plant gain
  • Controller gain
  • Cheyne Stokes Breathing (CSB)
  • Carotid Body Function
  • Peripheral Chemoresponsiveness
  • Heart Failure
04

In context

Sleep Apnea, Central Reclassified

96 studies on the registry are indexed under Sleep Apnea, Central; 18 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 54 interventional studies indexed under Sleep Apnea, Central.

Browse Sleep Apnea, Central studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.

Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.

Compared within Sleep Apnea, Central, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Apnea Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)>15/hour with CAHI>5/hour, will be included with the experiments
  • Those with chronic, stable heart failure with reduced , receiving stable optimized guideline-based therapy and no hospitalizations or change in the medical regimen for the past 90 days before enrollment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Moderate or severe obstructive or restrictive lung disease, including supplemental oxygen (O2) use
  • Current treatment for central sleep apnea (CSA), including any form of positive airway pressure (PAP) in the past three months, or phrenic nerve situation
  • Too ill to engage in the study procedures, inability to provide consent for participation
  • A history of cardiac arrhythmia
  • Alcohol or substance abuse (less than 90 days sobriety) or current participation in a treatment program
  • Depression or a history of suicidality
  • Severe insomnia (ISI>21) or reported short sleep duration (\<6 hours)
  • Positive airway pressure (PAP)-emergent central sleep apnea
  • Lack of positive airway pressure (PAP) acceptance/adherence after a one-week home PAP trial after enrollment

Additional Trazodone Exclusions:

  • Prolonged on baseline (ECG), using medications that inhibit
  • Patients with severe renal impairment ( (GFR) \< 20 milliliters per minute/1.73 square meters) or end-stage renal disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Trazodone

    To determine the effect of dampening respiratory arousals. The investigators hypothesize that positive airway pressure (PAP) therapy with trazodone at 100 milligrams will be superior to CPAP alone in widening the carbon dioxide (CO2) reserve during sleep, decreasing respiratory arousals, and increasing the arousal threshold.

    Drug: Trazodone + positive airway pressure (PAP) therapy

  • Active comparator
    Oxygen

    To determine the effect of dampening peripheral chemoreceptor sensitivity. The investigators hypothesize that supplemental oxygen will be superior to CPAP alone in widening the carbon dioxide (CO2) reserve during sleep. The secondary analysis will use CAI as supplemental oxygen, which may obscure the detection of hypopneas based on desaturation.

    Drug: Oxygen + positive airway pressure (PAP) therapy

Interventions

  • DrugTrazodone + positive airway pressure (PAP) therapy

    Drug page: TrazodoneStudies of TrazodoneTrazodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The central apnea index and the apneic threshold will be compared under two conditions: trazodone or placebo. In addition, participants will get PAP therapy during both the conditions.

  • DrugOxygen + positive airway pressure (PAP) therapy

    Drug page: OxygenStudies of OxygenOxygen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The central apnea index and the apneic threshold will be compared under two conditions: oxygen or room air. In addition, participants will get PAP therapy during both the conditions.

07

What researchers measure

Primary outcomes

  1. Carbon dioxide (CO2) Reserve

    CO2 reserve is the requisite change to induce central apnea to as the CO2 reserve, which can be positive or negative.

    Time frame: 120 days

Secondary outcomes

  1. Peripheral Chemoresponsiveness

    Peripheral chemoreflex sensitivity/Peripheral chemoresponsiveness is measured either via brief hypoxia or a single breath of carbon dioxide (CO2).

    Time frame: 120 days

  2. Arousal Threshold

    Arousal threshold is a measure of the upper airway muscle response to an obstructive sleep event.

    Time frame: 120 days

  3. Carotid body function

    This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.

    Time frame: 120 days

  4. Controller gain

    Controller gain is a ventilatory response to changes in end-tidal PCO2.

    Time frame: 120 days

  5. Plant gain

    Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating carbon dioxide (CO2).

    Time frame: 120 days

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jun 2030, 45 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 7, 2025
StartActual
Sep 16, 2026was Oct 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Dec 31, 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
John D. Dingell VA Medical Center, Detroit, MI is now Recruiting
Oct 13, 2026
Start date
Oct 1, 2026→Sep 16, 2026 (actual)
Oct 13, 2026
Eligibility
6 exclusion criteria edited, 1 removed
What changed in the criteria
Exclusion criteria
  • Removedless than 18 years old
  • EditedmoderateModerate or severe obstructive or restrictive lung disease, including supplemental o2oxygen (O2) use
  • EditedcurrentCurrent treatment for central sleep apnea (CSA), including any form of positive airway pressure (PAP) in the past three months, or phrenic nerve situation.
  • EditedPositive airway pressure (PAP)-emergent central sleep apnea
  • EditedLack of positive airway pressure (PAP) acceptance/adherence after a one-week home PAP trial after enrollment.
  • EditedProlonged QT on baseline electrocardiogram (ECG), using medications that inhibit CYP3A4
  • EditedPatients with severe renal impairment (glomerular filtration rate (GFR) < 20ml/min20 milliliters per minute/1.73m273 square meters) or end-stage renal disease
Oct 13, 2026
Interventions
Added Drug: Trazodone + positive airway pressure (PAP) therapy·Drug: Oxygen + positive airway pressure (PAP) therapy; removed Drug: Trazodone + PAP therapy·Drug: Oxygen + PAP therapy
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCarbon dioxide (CO2) ReserveTime frame: 120 days
Oct 13, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionPeripheral Chemoresponsiveness: how it is measured was reworded
  • DescriptionPlant gain: how it is measured was reworded
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • John D. Dingell VA Medical Center, Detroit, MI · Detroit, United StatesContact S•••@va.gov · •••4451→s•••@med.wayne.edu · •••1000
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    John D. Dingell VA Medical Center, Detroit, MI is now Recruiting
    Start date Oct 1, 2026→Sep 16, 2026 (now actual)
    Eligibility 6 exclusion criteria edited, 1 removed
    What changed in the criteria
    Exclusion criteria
    • Removedless than 18 years old
    • EditedmoderateModerate or severe obstructive or restrictive lung disease, including supplemental o2oxygen (O2) use
    • EditedcurrentCurrent treatment for central sleep apnea (CSA), including any form of positive airway pressure (PAP) in the past three months, or phrenic nerve situation.
    • EditedPositive airway pressure (PAP)-emergent central sleep apnea
    • EditedLack of positive airway pressure (PAP) acceptance/adherence after a one-week home PAP trial after enrollment.
    • EditedProlonged QT on baseline electrocardiogram (ECG), using medications that inhibit CYP3A4
    • EditedPatients with severe renal impairment (glomerular filtration rate (GFR) < 20ml/min20 milliliters per minute/1.73m273 square meters) or end-stage renal disease
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCarbon dioxide (CO2) ReserveTime frame: 120 days
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionPeripheral Chemoresponsiveness: how it is measured was reworded
    • DescriptionPlant gain: how it is measured was reworded
    Interventions Added Drug: Trazodone + positive airway pressure (PAP) therapy·Drug: Oxygen + positive airway pressure (PAP) therapy; removed Drug: Trazodone + PAP therapy·Drug: Oxygen + PAP therapy
    Site contacts Changed at 1 site. See the sites
    Show the site
    • John D. Dingell VA Medical Center, Detroit, MI · Detroit, United StatesContact S•••@va.gov · •••4451→s•••@med.wayne.edu · •••1000
    + 4 other changes: index terms, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07210606
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Sep 16, 2026
Primary completion
Jun 30, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

M S Badr, MD
Contact
sbadr@med.wayne.edu
(313) 576-1000 ext. 65710
M Safwan Badr, MD
principal investigator · John D. Dingell VA Medical Center, Detroit, MI

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trazodone · Oxygen

Start the discussion